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Abstract
Increased levels of the nuclear export protein, exportin 1 (XPO1), were demonstrated in multiple myeloma (MM)
patients. Targeting XPO1 with selinexor (the selective inhibitor of nuclear export; SINE compound KPT-330)
demonstrates broad antitumor activity also in patient cells resistant to bortezomib; hence, it is a promising target inMM
patients. Hypoxia is known tomediate tumor progression and drug resistance (including bortezomib resistance) inMM
cells. In this study, we tested the effects of selinexor alone or in combinationwith bortezomib in normoxia and hypoxia
on MM cell survival and apoptosis in vitro and in vivo. In vitro, selinexor alone decreased survival and increased
apoptosis, resensitizingMMcells to bortezomib. In vivo, we examined the effects of selinexor alone on tumor initiation
and tumor progression, aswell as selinexor in combinationwith bortezomib, on tumor growth in a bortezomib-resistant
MM xenograft mouse model. Selinexor, used as a single agent, delayed tumor initiation and tumor progression,
prolonging mice survival. In bortezomib-resistant xenografts, selinexor overcame drug resistance, significantly
decreasing tumor burden and extending mice survival when combined with bortezomib.
Translational Oncology (2017) 10, 632–640
Introduction
Multiplemyeloma (MM) is a plasma cellmalignancy localized primarily
in the bone marrow (BM). Some of the most novel therapies being
developed are based on interrupting the interactions between MM
cancer cells and the supportive BM microenvironment, which
contributes to pathogenesis and facilitates MM progression [1]. The
introduction of these therapeutics, including proteasome inhibitors
(such as bortezomib, carfilzomib and ixazomib), immunomodulatory
drugs, and monoclonal antibodies, substantially improved the survival
of MM patients [1–3]; however, more than 90% of MM patients
relapse [1,4]. Bortezomib is the first-in-class reversible proteasome
inhibitor which has been used as the backbone of frontline therapy and
relapsed/refractory settings in combination regimen in MM patients;
nevertheless, its use is limited due to the development of drug resistance
and side effects [5].
Exportin 1 (XPO1), also known as chromosome region maintenance
1, is the main nuclear exporter of leucine-rich proteins through the
nuclear pore complex to the cytoplasm, which is driven by guanosine
triphosphate hydrolysis [6]. This tightly controlled protein shuttling is
deregulated in cancer cells, where some of the XPO1 cargo proteins, such
as tumor suppressors (p53 [7,8], p21, and p27 [9]) and inhibitor of
NFκB [10,11], are abnormally localized in the cytosol and thus cannot
properly function in suppressing cancer initiation and progression [9].
Overexpression of XPO1 protein is associated with tumor growth and
poor patient survival as demonstrated in solid tumors including lung,
pancreatic, cervical, and ovarian cancers [8,12–14]; melanoma; glioma;
and osteosarcoma [15,16], as well as in hematologic malignancies
including acute myeloid leukemia [17], non-Hodgkin lymphoma [18],
andMM [11,19,20]. Interestingly, whole-genome sequencing in chronic
lymphocytic leukemia patients identified recurring mutations in the
highly conserved region of XPO1, suggesting that these oncogenic
changes may contribute to the clinical evolution of the disease [21,22].
Inhibition of the XPO1 proteinmediated by selective inhibitor of nuclear
export (SINE) compounds, developed by Karyopharm Therapeutics, has
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shown broad preclinical antitumor activity in many solid and
hematologic malignancies independent of p53 status [15,23–25].
SINE is currently in several phase I/II/III clinical trials including more
than 20 studies for myeloma patients, both newly diagnosed and
relapsed/refractory, in combination with different treatments.
Tai et al. have shown previously that XPO1 protein expression is
higher in MM cells in newly diagnosed patients as compared to normal
plasma cells [20]. Moreover, XPO1 mRNA expression is augmented
with MM disease progression and correlates with bone lytic lesions and
poor patient survival. It was reported that XPO1 protein plays a crucial
role in MM pathophysiology, malignant growth, and cancer cell
survival. These findings are based on XPO1 knockdown studies inMM
cells which were also mimicked using SINE (KPT-185, KPT-251,
KPT-276, and KPT-330). KPT-185 and KPT-330 were the most
potent XPO1 inhibitors, which significantly decreased MM cell
proliferation, induced cytotoxicity of MM cells, and increased the
percentage of apoptotic MM cells that were associated with inhibited
export of tumor suppressors such as p53, p27, PP2A, and FOXO3a. In
addition, it was shown that KPT-185 and KPT-330 inhibited
osteoclastogenesis and bone resorption via reducing NFκB activity;
however, they did not affect osteoblastogenesis in vivo [20].
Therapy resistance acquired byMMcells is one of themain problems
in MM treatment and tumor recurrence. Interestingly, XPO1 protein
and mRNA levels were demonstrated to be increased during MM
progression, and MM cells isolated from patients resistant to
bortezomib expressed higher XPO1 protein levels [20]. These results
suggest that XPO1 could potentially be a biomarker of cancer
progression as well as development of drug resistance inMM. Likewise,
tumor hypoxia (low oxygenation) is a phenomenon observed in growing
malignant tumors, and hypoxia-induced genes have been used in
detecting MM tumor growth and drug resistance [26,27]. We and
others have shown that tumor hypoxia develops due to uncontrollable
MM cell proliferation and correlates with poor prognosis of cancer
patients [28–30]. Hypoxia confers treatment resistance of cancer cells
by regulating processes such as quiescence via cell cycle arrest [31–33];
inhibiting apoptosis and senescence of cells; controlling autophagy,
endoplasmic reticulum (ER) stress, and p53 and mitochondrial activity
[26,32]; and maintaining stem cell–like phenotype through induction
of dedifferentiated and immature phenotype of cells [34–37]. We have
previously tested the role of hypoxia in MM cell proliferation in the
presence of proteasome inhibitors, where MM cells were cultured in
hypoxic and normoxic conditions and subsequently treated with or
without bortezomib and carfilzomib. We have shown that, in hypoxic
conditions, cancer cells lose their sensitivity to proteasome inhibitors
in vitro [27].
In this study, we examined whether inhibiting XPO1 with the oral,
slowly reversible inhibitor selinexor resensitized hypoxia-induced
drug resistance to bortezomib in MM. Indeed, selinexor reversed the
hypoxia-induced resistance to bortezomib in MM cells both in vitro
and in vivo, thus providing evidence for clinical trials combining
proteasome inhibitors with XPO1 inhibition.
Materials and Methods
Cell Culture
The MM cell lines (MM.1S and MM.1S-GFP-Luc) were a kind
gift from Dr. Irene Ghobrial (Dana-Farber Cancer Institute in
Boston, MA). Cells were cultured in RPMI-1640 (Corning CellGro,
Mediatech, Manassas, VA) supplemented with 10% fetal bovine
serum (Gibco, Life Technologies, Grand Island, NY), 2 mmol/l of
L-glutamine, 100 U/ml of penicillin, and 100 μg/ml of streptomy-
cin (CellGro, Mediatech, Manassas, VA). Cells were cultured at
37°C and 5% CO2 in a humidified tissue culture incubator (21%
O2), in the NuAire water jacket incubator (Plymouth, MN), or in
hypoxia (1% O2) using the hypoxic chamber purchased from Coy
(Grass Lake, MI).
Selinexor (KPT-330)
Selinexor (KPT-330) was provided by Karyopharm Therapeutics
(Newton, MA). For in vitro experiments, selinexor was solubilized in
dimethylsulfoxide, aliquoted, and stored at −80°C. For in vivo studies,
the selinexor formulated drug product contained ~70% active
ingredient, ~15% Plasdone PVP K-29/32, and ~15% Poloxamer
Pluronic F-68 (provided by Karyopharm Therapeutics) and was stored
at 4°C for 7 days. Plasdone PVP K-29/32 with Poloxamer Pluronic
F-68 served as a vehicle in the mice studies.
Effects of Selinexor on MM Cell Survival
Cell survival was assessed using MTT solution (Sigma-Aldrich,
St. Louis, MO), followed by absorbance measurement at 570 nm using
a spectrophotometer according to the manufacturers' protocol, where
the absorbance is proportional to the number of viable cells. The effects
of increasing concentrations of selinexor (KPT-330; 0, 100, 250,
and 500 nM), bortezomib (Selleck Chem, Houston, TX; 10 nM),
and combination treatment (100 nM of KPT-330 and 10 nM of
bortezomib) were tested on MM cell survival/cytotoxicity under
normoxic and hypoxic conditions for 24 hours. In addition, the effect
of selinexor (0, 50, 100, and 250 nM) and bortezomib (0, 1, 5, and
10 nM) was examined on MM.1S cell survival in normoxic conditions
by MTT.
Effect of Selinexor on MM Cell Apoptosis
Cell apoptosis was performed using Annexin V–propidium iodide (PI)
staining (BD Biosciences, San Jose, CA) according to the manufacturer's
protocol. Briefly, MM.1S cells (1 × 106 cell/ml) were cultured with
selinexor (0, 100, 250, and 500 nM) with or without bortezomib
(10 nM) for 24 hours. Then, cells were washed and resuspended in 1×
Annexin binding buffer, followed by Annexin V staining for 15 minutes
and PI staining for additional 15 minutes, and analyzed with
MACSQuant Flow Cytometer (Miltenyi, San Diego, CA). The results
were demonstrated as a frequency (%) of viable (Ann−PI−), early
apoptotic (Ann+PI−), and late apoptotic/dead (Ann+PI+) MM cells
posttreatment.
Western Blotting
To test cell signaling involved in proliferation, apoptosis, and cell
cycle, MM cells were first treated with selinexor (0, 100, 250, and
500 nM) with or without bortezomib (10 nM) in normoxia or hypoxia
for 24 hours. Cells were collected, washed with 1× PBS, and lysed for
30 minutes on ice using 1× lysis buffer (Cell Signaling, Danvers, MA).
Protein concentration was assessed by Quick Start Bradford dye reagent
(BioRad, Hercules, CA). Sodium dodecyl sulfate–polyacrylamide gel
electrophoresis was performed using NuPAGE 4% to 12% Bis-Tris gels
(Novex, Life Technologies, Grand Island, NY) and transferred to a
nitrocellulose membrane using iBlot (Invitrogen, Life Technologies).
Membranes were blocked with 5% skim milk in Tris-buffered saline/
Tween 20 buffer and incubated with primary antibodies overnight at
4°C for apoptosis signaling (cleaved PARP, cPARP; cleaved caspase-3,
cCasp3; cCasp8), proliferation signaling (p-p44/42MAPK; p-S6R), and
cell cycle signaling (p-Rb; CDK-6). α-Tubulin was used as a loading
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control (antibodies were purchased fromCell Signaling). Themembrane
was washed with Tris-buffered saline/Tween 20, incubated for 1 hour at
room temperature with HRP-conjugated secondary antibody, then
washed and developed using Novex ECL Chemiluminescent Substrate
Reagent Kit (Invitrogen). The density of bands was quantified using
ImageJ Software and normalized to α-Tubulin.
Animal Studies: Tumor Initiation, Tumor Progression, and
Survival Study
SCID-beige mice (females, 8 weeks old) were obtained from Charles
Rivers Laboratories (Wilmington, MD). Approval for these studies was
obtained from the Ethical Committee for Animal Experiments at
Washington University in St. Louis School of Medicine.
For the tumor initiation study, 10 mice were injected intravenously
(IV) with MM.1S-GFP-Luc cells at the concentration of 3 × 106 cells
per mouse and were treated instantaneously with vehicle (n = 5) or
selinexor (15 mg/kg, n = 5) administered by oral gavage (PO) three
times a week (TIW at day 1, 3, and 5). Mice survival was recorded
daily, whereas mice weight and tumor growth using bioluminescent
imaging (BLI) were monitored at day 0, 28, and 42.
In the tumor progression study, MM.1S-GFP-Luc cells were
injected IV into 16 SCIDmice at a concentration of 2 × 106 cells per
mouse and allowed to grow for 3 weeks; the tumor growth was
determined by BLI. At week 3, mice were randomly allocated into
two groups (eight mice per group) which received vehicle (n = 8) or
selinexor (15 mg/kg; n = 8). Vehicle and selinexor were adminis-
tered by oral gavage three times a week (TIW at day 1, 3, and 5).
Survival of mice was monitored every day by the investigator,
whereas mice weight and tumor growth (BLI) were examined at day
0, 21, and 28.
To test the effect of selinexor on bortezomib-resistant cancer, first we
demonstrated development of xenograft mouse model resistant to
bortezomib. MM.1S-GFP-Luc cells were injected IV into 16 SCID
mice at a concentration of 2 × 106 cells per mouse and allowed to grow
for 3 weeks when the tumor burden was determined by BLI.Mice with
established MM tumors were pretreated with vehicle (n = 8) or
bortezomib (n = 8; 1.0 mg/kg) administered intraperitoneally (IP)
twice a week (BIW) for 2 weeks. A treatment with bortezomib showed
initial response in the first week and then relapsed in week 2,
demonstrated as ROI normalized to tumor size before pretreatment
(Supplementary Figure 1).
Finally, to test the effect of selinexor on bortezomib-resistant cancer,
MM.1S-GFP-Luc cells were injected IV into 24 SCID mice at a
concentration of 2 × 106 cells per mouse and allowed to grow for
3 weeks, confirmed by BLI. Thenmice were pretreated with bortezomib
(1.0 mg/kg) for the next 2 weeks to induce resistance to bortezomib,
after which the mice were randomly allocated (day 14) into 3 groups
as follow: (1) bortezomib (0.5 mg/kg; n = 8) alone, (2) selinexor
(10 mg/kg; n = 8) alone, and (3) a combination of selinexor (10 mg/kg)
and bortezomib (0.5 mg/kg; n = 8). Bortezomib was injected IP twice a
week (BIW; day 1 and day 4), and selinexor was administered by oral
gavage three times a week (TIW; day 1, 3, and 5) along with vehicle
controls. Survival of mice was monitored every day by the investigator,
whereas mice weight and tumor growth (BLI) were examined at day 0,
14, 21, 35, and 42.
Statistical Analysis
The in vitro experiments were performed in quadruples and
replicated independently at least three more times. Results are shown
as mean ± S.D., and statistical significance was analyzed using
Student’s t test. The in vivo data were analyzed using Student’s t test
for statistical significance, and results are depicted as mean ± S.E.M.
Variation within each group was equally variant and similar between
the groups that were statistically compared. Values were considered
significantly different for P values less than .05.
Results
Selinexor Inhibits Survival and Induces Apoptosis in a
Dose-Dependent Manner in MM.1S Cells
Within 24 hours, in vitro studies showed that selinexor dose-
dependently decreased the survival of both normoxic and hypoxic
MM.1S cells (Figure 1A), whereas it increased the percentage (%) of
apoptotic and dead cells in normoxic and hypoxic cells (Figure 1B).
The mechanism of selinexor-induced cell apoptosis was based on its
effects on the expression of the cell signaling proteins (cleaved PARP,
Casp3, and Casp8), which was regulated in a dose-dependent manner
in both conditions. On the contrary, phosphorylation of ERK1/2 and
S6R (proteins involved in cell proliferation) was decreased with
increasing concentrations of selinexor, as demonstrated by the
intensity of the bands (Figure 1Ci) and by quantitative densitometry
(Figure 1Cii). The effect of selinexor concentrations was more
pronounced in hypoxic than normoxic conditions.
Selinexor Reverses Hypoxia-Induced Resistance to Bortezomib
In Vitro
We have previously demonstrated the development of drug
resistance to proteasome inhibitors in hypoxic conditions in MM
cell lines [27]. Using the MTT assay, we showed that the
combination of selinexor and bortezomib increased the cytotoxic
effect of bortezomib and overcame hypoxia-induced resistance to
bortezomib (Figure 2A). Similarly, the apoptosis assay showed that
the combination of bortezomib and selinexor increased the % of
apoptotic and dead cells compared to bortezomib alone, especially in
hypoxia (Figure 2B). Mechanistically, the combination of selinexor
with bortezomib induced greater cleavage of PARP, Casp3, and
Casp8; decreased phosphorylation of Rb; and downregulated the
expression of CDK-6 compared to bortezomib alone; there was
almost complete abrogation of the latter two proteins, as demon-
strated by the intensity of the bands (Figure 2Ci) and by quantitative
densitometry (Figure 2Cii). These results imply halted cell cycle and
hence reduced cell proliferation. We tested the effect of combination
of increasing concentrations of bortezomib and selinexor on MM.1S
cell survival, and we found that the combination had an additive
effect, and no synergy was observed (Figure 2D).
Selinexor as a Single Agent Delays Tumor Initiation and
Improves Mice Survival
Next, we tested the effects of selinexor (15 mg/kg) as a single
agent on tumor initiation in vivo. On the first day following
MM.1S-GFP-Luc cell injection, we initiated oral gavage treatment
of selinexor three times a week (TIW) (see the schematic diagram in
Figure 3A). Selinexor delayed tumor initiation, which was detectable
in the vehicle-treated group 28 days after treatment (Figure 3B,
P = .034). At 42 days after treatment, the tumor burden in the
selinexor-treated group was nearly half that of the vehicle-treated group
(P = .078) (Figure 3B).Moreover, the vehicle-treated mice deteriorated
rapidly and stayed on the study until day 53, whereas mice treated with
selinexor stayed on the study for 10 more days until day 63 (P = .007)
(Figure 3C).
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Selinexor as a Single Agent Delays Tumor Progression in
MM-Bearing Mice
Next, we tested the effects of selinexor (15 mg/kg) as a single agent
on tumor progression inMM-bearing mice administered by oral gavage
three times a week (TIW). Treatment started 3 weeks post–MM cell
injection (see the schematic diagram in Figure 4A). Selinexor
significantly delayed tumor progression and reduced tumor burden
by approximately half when compared to the vehicle-treated group at 21
and 28 days post–treatment initiation (P = .032) (Figure 4B).
Moreover, selinexor-treated mice survived significantly longer than
vehicle-treated mice; the vehicle-treated group stayed on the study until
36 days after treatment initiation, whereas the selinexor-treated group
stayed on the study until 42 days after treatment initiation (P = .014)
(Figure 4C).
Combination of Selinexor with Bortezomib Delays Tumor
Growth and Improves Survival in Bortezomib-Resistant
MM-Bearing Mice
First, we emulated MM disease refractory to bortezomib by
demonstrating that the initial administration of bortezomib alone in
established MM mouse model caused bortezomib resistance. Three
weeks post–MM cell injection to mice, mice were treated with vehicle
(n = 8 mice) or bortezomib (n = 8; 1.0 mg/kg). Whereas the MM
tumor constantly grew over 2 weeks in the vehicle-treated group, a
Figure 1. Selinexor inhibits survival and induces apoptosis in a dose-dependent manner in MM cells. Cell survival and apoptosis of MM.1S
cells treated with increasing concentrations of selinexor for 24 hours in normoxic and hypoxic conditions using (A) a survival/cytotoxic
MTT assay, (B) an apoptosis assay based on Annexin V/PI staining, and (Ci) immunoblotting analyses of proteins involved in apoptosis and
proliferation, with (Cii) the densitometric analysis from a representative study performed on MM.1S cells.
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treatment with bortezomib showed initial response in the first week and
then relapse inweek 2 (Supplementary Figure 1).We therefore used this
mouse model to examine the effect of selinexor, with and without
bortezomib, on tumor growth in bortezomib-resistant MM-bearing
mice (see the schematic diagram in Figure 5A). Mice with established
tumors were first treated with bortezomib IP two times a week (BIW),
for 2 weeks, to induce resistance to bortezomib. Mice were then
randomized and treated with bortezomib alone, selinexor alone, or the
combination of bortezomib and selinexor. At day 35 (21 days after the
randomization) and at day 42 (28 days after the randomization), tumor
burden in mice treated with the combination of selinexor and
bortezomib was 60% smaller than in mice treated with bortezomib
alone (P = .012 and .036, respectively) (Figure 5B). Similarly, the
survival of mice treated with the combination of selinexor and
bortezomib was significantly longer than that of mice treated with
bortezomib alone, in which the group treated with bortezomib alone all
Figure 2. Selinexor reverses hypoxia-induced resistance to bortezomib in vitro. (A) Cell survival of MM.1S cells treated with selinexor
(100 nM) in combination with bortezomib (10 nM) for 24 hours in normoxic and hypoxic conditions using a survival/cytotoxic MTT assay;
(B) apoptosis assay based on Annexin V/PI staining, and (Ci) immunoblotting analyses of proteins involved in apoptosis and cell cycle, with
(Cii) densitometric analysis. (D) The effect of selinexor (0, 50, 100, and 250 nM) in combination with bortezomib (0, 1, 5, and 10 nM) on
MM.1S survival using MTT assay.
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died at day 50, whereas 50% of the mice in the group treated with
the combination of bortezomib and selinexor were still alive at day 52
(P = .005) (Figure 5C).
Discussion
Despite the implementation of novel therapies (which include
proteasome inhibitors), the majority of MM patients relapse due to
the development of drug resistance [38]. Low oxygenation (hypoxia) in
the BMmicroenvironment was shown to occur beyond physiologic BM
conditions during the progression of MM and, together with cellular
and acellular components, plays a critical role in MM dissemination,
stem cell–like properties, and drug resistance [27,30,39]. Our research
group reported enhanced MM drug resistance to current therapies,
including bortezomib and carfilzomib, in hypoxic MM cells [27,40].
Therefore, targeting hypoxic cells to abolish the drug-resistant cancer
population is the vital goal to prevent recurrence in MM patients.
Increased levels of XPO1, the nuclear exporter of tumor suppressors,
were observed in MM. Moreover, XPO1 was shown to be upregulated
in MM cells from patients who became resistant to bortezomib,
suggesting that XPO1 could be involved in drug resistance [20].
Because hypoxia has been known to be involved in developing
treatment resistance, we hypothesized that inhibition of XPO1 using
the novel, orally available inhibitor selinexor (KPT-330) will reverse
the hypoxia-induced bortezomib resistance in MM cells both in vitro
and in vivo.
In vitro, we have demonstrated that selinexor as a single agent
increased apoptosis and decreased survival of MM cells in both
normoxia and hypoxia in a dose-dependent manner. In addition,
combination treatment of selinexor and bortezomib demonstrated an
additive effect on cell survival, and selinexor overcame hypoxia-induced
drug resistance to bortezomib in cell culture. In vivo, the tumor
initiation study inhibiting XPO1with selinexor as a single agent delayed
tumor progression, decreased tumor growth, and extended mice
survival, indicating that XPO1may be involved in tumorigenesis. In the
tumor progression study on MM-bearing mice, which exemplified
Figure 3. Selinexor as a single agent delays tumor initiation and
improves survival in mice. (A) Schematic diagram of mice treatment
regimen in the tumor initiation study where selinexor (15 mg/kg) was
given orally (PO) three times aweek (TIW) as a single agent the first day
following MM.1S-GFP-Luc cell injection. (B) Tumor burden in SCID
mice treated with vehicle (n = 5) or selinexor (15 mg/kg administered
by oral gavage three times per week, TIW; n = 5) determined by BLI
and shown as an ROI normalized to initial tumor size in each group
(mean ± S.E.M.). (C) Survival of mice depicted as Kaplan-Meier curve.
Figure 4. Selinexor as a single agent delays tumor progression in
MM-bearingmice. (A) Schematic diagramofmice treatment regimen
in the tumor progression study. (B) Tumor burden in MM-bearing
SCID mice treated with vehicle (n = 8) or selinexor (15 mg/kg
administered by oral gavage three times per week, TIW; n = 8)
determined by BLI and shown as an ROI normalized to initial tumor
size in each group (mean ± S.E.M.). (C) Survival of mice depicted as
Kaplan-Meier curve.
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newly diagnosed patients, selinexor used as a single agent significantly
reduced tumor burden and prolonged mice survival. These results were
in accordance with previously published data showing that XPO1
inhibitors decreased tumor size and increased survival in MM-bearing
mice as compared to the vehicle-treated group [11,20].
Next, we have mimicked MM patients with refractory disease
utilizing a xenograft mouse model resistant to bortezomib achieved by
pretreating MM-bearing mice with bortezomib, where bortezomib-
treated mice initially responded to chemotherapy but eventually
relapsed. In this study, we used the same method to develop the
bortezomib-resistant mouse model by pretreating mice with established
tumors with bortezomib before adding selinexor to the treatment.
Hence, this model emulates the refractory stage of the disease. These
in vivo results demonstrate that the combination of selinexor with
low-dose bortezomib in bortezomib-resistant MM-bearing mice
significantly decreased tumor growth and extended mice survival.
We suggest that the mechanism of the combined effect of bortezomib
and selinexor is related to protein homeostasis that each of these drugs
(and hypoxia) affects. Protein homeostasis is controlled by several
mechanisms such as protein synthesis, nuclear-cytoplasm protein
trafficking, protein folding in the ER, and protein recycling by
degradation in the proteasome [41]. By blocking XPO1 with SINE,
the nuclear-cytoplasm trafficking of the growth-promoting proteins and
oncogenic proteins is hampered, causing cell death [9,10]. Hypoxia was
shown to induce inhibition of protein synthesis through the mTOR
pathway, as well as induction of protein misfolding in the ER due to the
lack of recycling of glutathione for production of S-S bonds, ultimately
contributing to the ER stress [42,43]. Bortezomib is a proteasome
inhibitor that causes inhibition of protein recycling and accumulation of
abnormal and misfolded proteins by preventing their degradation in the
proteasome, triggering cell death [5]. Hence, we speculate that
subsequently the combination of selinexor with bortezomib, especially
Figure 5. Combination of selinexor with bortezomib delays tumor growth and improves survival in bortezomib-resistant MM-bearing
mice. (A) Schematic diagram of mice treatment regimen in the tumor progression study where the MM-bearing mice were pretreated
with bortezomib (1.0 mg/kg; administered IP twice a week, BIW) for 2 weeks to develop drug resistance. Mice were then randomized and
treated with bortezomib (0.5 mg/kg; n = 8), selinexor (10 mg/kg administered by oral gavage three times per week, TIW; n = 8), or
combination treatment (n = 8). (B) Tumor burden was determined by bioluminescence imaging (BLI) and shown as a ROI normalized to
tumor size after bortezomib pretreatment (mean ± S.E.M.). (C) Survival of mice depicted as Kaplan-Meier curve.
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in hypoxic conditions, perturbs intracellular protein homeostasis causing
protein overload in different cell compartments, induces cell stress, and
enhances anticancer activity. A more thorough investigation of the
mechanism is warranted.
In conclusion, we report that XPO1 inhibitor selinexor is an effective
antitumor agent and can overcome hypoxia-induced drug resistance;
hence, it represents a promising novel therapeutic strategy in treating
patients with MM. Selinexor decreased survival and increased apoptosis
of MM cells as a single agent in vitro and slowed down tumor initiation
and tumor progression in the xenograft MMmouse models, significantly
prolonging mice survival. In addition, selinexor dramatically reduced
tumor growth when combined with low-dose bortezomib in a
bortezomib-resistant xenograft model. These results provide further
support for current and future clinical trials to treat newly diagnosed aswell
as relapsed/refractoryMMpatients with selinexor, especially those who are
resistant to bortezomib (and possibly other proteasome inhibitors).
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